MAP2K1: a mutation that responds?

#Histiocytosis #MAPK #MEK #Cobimetinib #Trametinib #Neoplasia


Histiocytoses, such as Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD), are rare hematological neoplasms resulting from clonal proliferation of myeloid-derived cells. Long considered inflammatory disorders, they are now reclassified as neoplastic entities due to the discovery of activating mutations in the MAPK/ERK signaling pathway. Among these alterations, MAP2K1 mutations are frequently identified, particularly in patients without BRAF mutations.  

BRAF inhibitors have shown remarkable efficacy in BRAF^V600E-mutated forms, transforming disease management. In contrast, the clinical activity of MEK inhibitors in patients with MAP2K1 mutations remains poorly documented, especially in real-world settings outside of controlled clinical trials.  

This study was initiated to retrospectively evaluate the effectiveness of MAPK pathway inhibitors in patients with MAP2K1-mutated histiocytoses. It also aimed to assess treatment tolerability, efficacy in complex visceral sites including the brain, and durability of the responses.  

MEK inhibitors: a turning point for histiocytoses?  

Twenty-four patients with histiocytoses (ECD, RDD, or mixed forms) harboring a MAP2K1 mutation were selected. These patients were treated between 2015 and 2023 with MAPK pathway inhibitors: cobimetinib (n = 20) or trametinib (n = 4). Most patients had multisystem involvement, including the central nervous system (CNS) in 38% of cases.  

The results showed an objective response in 63% of cases, including 21% complete responses, based on RECIST or radioclinical-biological criteria. Intracerebral activity was observed in several patients, with notable clinical improvement. Median duration of response was not reached at the time of analysis, with a median follow-up of 27 months.

In terms of safety, 50% of patients experienced grade ≥2 adverse events, primarily cutaneous, gastrointestinal, or muscular, requiring dose adjustments in 42% of cases. No treatment-related deaths were reported.  

Targeting MEK to stabilize disease?  

MAP2K1-mutated histiocytoses are rare myeloid neoplasms now recognized as clonal diseases with potential for progression. Their treatment remains challenging, particularly with visceral or neurological involvement, due to the lack of clinical data on targeted therapies outside of BRAF mutations.  

In this context, the study aimed to evaluate the real-world effectiveness and safety of MAPK pathway inhibitors—mainly cobimetinib and trametinib—in patients with MAP2K1 mutations.

The results confirm significant antitumor activity, including in brain lesions, with a favorable overall safety profile. These data support integrating MEK inhibitors as a targeted therapeutic strategy in this subgroup of patients.   However, the study has limitations, including its retrospective design, small sample size, and histological heterogeneity, which constrain the scope and generalizability of its conclusions. Larger prospective studies are needed to confirm these findings and refine the use of MEK inhibitors. Such studies should also help better characterize resistance mechanisms and identify predictive biomarkers to optimize personalized and long-term management of MAP2K1-mutated histiocytoses.  

Read next: Metastatic breast cancer: what still needs to be (re)considered?